Illustrative image.

Welireg

Name: Welireg
Brand: Merck
Availability: InStock

Belzutifan

Prescription required

$30940.00

40mg · 90 tablets · 3 months supply

BrandBranded medicine· By Merck

$10313.33 per month

How long a supply?

3 months$10313.33 a monthOne-off$30940.00

6 months$10313.33 a monthOne-off$61880.00

Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$123760a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningEmbryo-fetal toxicity

Exposure to WELIREG during pregnancy can cause embryo-fetal harm.

Verify pregnancy status prior to the initiation of WELIREG.

Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective.

Read this with the rest of the clinical information

About Welireg

Overview

Welireg (belzutifan) is a prescription medicine used in adults with von Hippel-Lindau (VHL) disease who need treatment for associated kidney cancer, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors that do not require immediate surgery. It also treats kidney cancer with a clear cell component in adults: after kidney removal, with or without removal of cancer that has spread, when recurrence risk is intermediate-high or high, alongside pembrolizumab or pembrolizumab with berahyaluronidase alfa-pmph; or on its own for advanced disease after treatment with both a PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. It is also used in adults and children aged 12 years and older for pheochromocytoma or paraganglioma that is locally advanced, cannot be removed surgically or has spread. Belzutifan blocks a protein called HIF-2α, reducing the activity of genes involved in cell growth, blood vessel formation and tumor growth.

What it treats

• Adults with von Hippel-Lindau (VHL) disease who need treatment for associated renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors that do not require immediate surgery. • Adults with renal cell carcinoma with a clear cell component at intermediate-high or high risk of recurrence after kidney removal, or after kidney removal and removal of metastatic lesions. Used with pembrolizumab or with pembrolizumab and berahyaluronidase alfa-pmph. • Adults with advanced renal cell carcinoma with a clear cell component, used alone after treatment with both a PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. • Adults and children aged 12 years and older with pheochromocytoma or paraganglioma that is locally advanced, cannot be removed surgically or has spread to other parts of the body.

Safety information

Side effects

Common side effects reported with Welireg include tiredness, headache, dizziness, nausea, muscle and joint pain, and shortness of breath. Which effects are most common varies by the condition being treated and whether Welireg is used alone or with pembrolizumab. Common blood test changes include low hemoglobin (anemia), reduced white blood cells, increased creatinine, increased liver enzymes, increased blood sugar, low sodium, and increased potassium or calcium. Serious side effects include anemia and low oxygen levels (hypoxia), which can be life-threatening. Contact your doctor if you develop shortness of breath or are told that your hemoglobin or oxygen level is low. Your doctor should check for anemia and monitor oxygen levels before treatment and periodically during treatment. These side effects may require treatment to be paused or stopped; life-threatening hypoxia requires Welireg to be stopped permanently.

FDA boxed warning

Embryo-fetal toxicity

Exposure to WELIREG during pregnancy can cause embryo-fetal harm.

Verify pregnancy status prior to the initiation of WELIREG.

Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek medical attention immediately for shortness of breath. - Contact your doctor immediately if you become pregnant or think you may be pregnant; Welireg can harm an unborn baby.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The supplied FDA label lists no contraindications for Welireg. Welireg requires monitoring for anemia and low blood oxygen levels before treatment and periodically during treatment. Depending on severity, the prescriber may pause treatment, reduce the dose or stop treatment permanently. Life-threatening low blood oxygen requires permanent discontinuation. Do not breastfeed during treatment. Welireg may impair fertility in males and females.

Interactions

Tell your doctor about all medicines you take. Medicines that inhibit UGT2B17 or CYP2C19 require monitoring for anemia (low red blood cell levels) and hypoxia (low oxygen levels) when taken with Welireg. Your doctor may need to adjust your treatment. Welireg should not be taken with certain medicines processed by CYP3A4 if even a small decrease in their levels could make them less effective. Ask your doctor to check whether this applies to any of your medicines.

Using Welireg

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label WELIREG (BELZUTIFAN) TABLET, FILM COATED [MERCK SHARP & DOHME LLC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.